GILD Gilead Sciences, Inc. stock chart & analysis
Conviction 37HealthcareScan · Fri, Nov 6, 2026Gilead Sciences, Inc. (GILD) closed at $166.89 (-0.41%) on Nov 6, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 60, RS Rating 94, -5.5% from its 52-week high, +35.9% year to date. Sector: Healthcare · Biological Products, (No Diagnostic Substances).
Financials as of Wed, Sep 30, 2026 · quarterly.
GILD technical analysis
Trend
GILD is in an uptrend: price is above the 50-day, which is above the 200-day moving average. It closed 9.0% above the 50-day ($153.04) and 18.4% above the 200-day ($140.96). ADX(14) at 30 points to a strong, established trend. It meets 6 of 8 trend-template criteria.
Momentum
RSI(14) is 60, in the bullish half of its range. The MACD histogram is positive. Its RS Rating of 94 puts its weighted 12-month performance ahead of about 94% of the US market.
Volume and volatility
Volume on the latest session ran 0.6× its 20-day average. It trades about $1.1B a day on average. ATR(14) is $5.15, 3.1% of price — its typical daily range. Chaikin Money Flow (-0.06) shows distribution.
Key levels
The chart pattern's support is $145.31 and its resistance $168.08. The 52-week range is $116.88 to $176.58; price is 5.5% below the high and 42.8% above the low. The VWAP anchored at the 52-week high is $169.43, above price.
Performance
GILD returned -2.2% (1 week), +13.4% (1 month), +25.4% (3 months), +27.1% (6 months), +36.1% (1 year), +35.9% (year to date).
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Biological Products, (No Diagnostic Substances) · Listed 1992 · 17,000 employees
Congress activity
Disclosed STOCK Act trades in GILD · 10 recent
| Member | Side | Amount | Traded | Filed | PTR |
|---|---|---|---|---|---|
 Thomas H Tuberville senate · traded 2024-05-10 | Buy | $1K–$15K | 2024-05-10 | 2026-08-05 | |
Thomas H Tuberville senate · traded 2024-05-08 | Sell | $1K–$15K | 2024-05-08 | 2026-08-05 | |
 Alan Armstrong senate · R · OK · traded 2026-03-27 | Buy | $1K–$15K | 2026-03-27 | 2026-07-21 | |
 Jared Moskowitz house · D · FL · traded 2026-05-06 | Buy | $1K–$15K | 2026-05-06 | 2026-06-19 | |
 Josh Gottheimer house · D · NJ · traded 2026-01-27 | Buy | $1K–$15K | 2026-01-27 | 2026-02-26 | |
 Valerie Hoyle house · D · OR · traded 2025-09-23 | Sell | $1K–$15K | 2025-09-23 | 2025-10-10 | |
Valerie Hoyle house · D · OR · traded 2024-10-29 | Buy | $1K–$15K | 2024-10-29 | 2025-09-12 | |
 Jefferson Shreve house · R · IN · traded 2025-05-12 | Sell | $15K–$50K | 2025-05-12 | 2025-06-22 | |
 Marjorie Taylor Greene house · GA · traded 2025-06-06 | Buy | $1K–$15K | 2025-06-06 | 2025-06-18 | |
Josh Gottheimer house · D · NJ · traded 2025-05-14 | Sell | $1K–$15K | 2025-05-14 | 2025-06-11 |
Insider activity
SEC Form 4 transactions in GILD · open-market 6 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
O'Day Daniel Patrick Chairman & CEO · Common Stock · 2026-11-05 | Exercise | 9.81K | $710K | 2026-11-05 | 2026-11-06 |
O'Day Daniel Patrick Chairman & CEO · Common Stock · 2026-11-05 | Sell | 9.81K | $1.7M | 2026-11-05 | 2026-11-06 |
O'Day Daniel Patrick Chairman & CEO · Non-qualified Stock Option (Right to Buy) · 2026-11-05 | Exercise | 9.81K | — | 2026-11-05 | 2026-11-06 |
O'Day Daniel Patrick Chairman & CEO · Common Stock · 2026-11-04 | Exercise | 102.62K | $7.4M | 2026-11-04 | 2026-11-06 |
O'Day Daniel Patrick Chairman & CEO · Common Stock · 2026-11-04 | Sell | 102.62K | $18M | 2026-11-04 | 2026-11-06 |
O'Day Daniel Patrick Chairman & CEO · Non-qualified Stock Option (Right to Buy) · 2026-11-04 | Exercise | 102.62K | — | 2026-11-04 | 2026-11-06 |
O'Day Daniel Patrick Chairman & CEO · Common Stock · 2026-11-02 | Sell | 1.9K | $322K | 2026-11-02 | 2026-11-02 |
O'Day Daniel Patrick Chairman & CEO · Common Stock · 2026-11-02 | Sell | 2K | $342K | 2026-11-02 | 2026-11-02 |
O'Day Daniel Patrick Chairman & CEO · Common Stock · 2026-11-02 | Sell | 1.6K | $268K | 2026-11-02 | 2026-11-02 |
O'Day Daniel Patrick Chairman & CEO · Common Stock · 2026-11-02 | Sell | 1.7K | $286K | 2026-11-02 | 2026-11-02 |
SEC filings
EDGAR filings in GILD · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.